Nonalcoholic Steatohepatitis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Intercept, AstraZeneca, Gilead, Pfizer, Alnylam, Eli Lilly and Company, Novo Nordisk

The nonalcoholic steatohepatitis market size is supposed to grow during the forecast period owing to the expected launch of novel emerging classes of drugs including FXR Agonists, FGF21 Stimulants, FGF19 Analog, Glucagon-like Peptide-1 (GLP-1) Agonist, Peroxisome Proliferator-activated Receptor (PPAR) Regulator, THR-β Agonist, and others, which shall fuel the growth of the market during the forecast period, i.e., 2023–2032.

LAS VEGAS, April 24, 2023 /PRNewswire/ -- DelveInsight's Nonalcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, nonalcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Nonalcoholic Steatohepatitis Market Report

• As per DelveInsight analysis, the nonalcoholic steatohepatitis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
• According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It's estimated that about 25% of adults in the US have NAFLD, and about 20% have NASH (5% of adults in the US). 
• Leading nonalcoholic steatohepatitis companies such as Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, AstraZeneca, Inventiva Pharma, Cirius Therapeutics, Inc, Galectin Therapeutics Inc., Galmed Research and Development, Ltd., Zydus Therapeutics Inc., Rivus Pharmaceuticals, Inc., 89bio, Inc., Lipocine Inc., HighTide Biopharma Pty Ltd, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc., CytoDyn, Inc., Terns, Inc., Poxel SA, Enanta Pharmaceuticals, Inc, Kowa Company, Ltd., NorthSea Therapeutics B.V., Merck, NGM Biopharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, Gilead Sciences, Cascade Pharmaceuticals, Inc, Hepion Pharmaceuticals, Inc., Pfizer, Alnylam Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Future Medicine, Boston Pharmaceuticals, MediciNova, Cellaion, Promethera Therapeutics, Viking Therapeutics, Inc., Novo Nordisk A/S, Eccogene, CohBar, Inc., Aligos Therapeutics, Corcept Therapeutics, Altimmune, Inc., Janssen Pharmaceutical K.K., Enanta Pharmaceuticals, Inc, Arrowhead Pharma, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Novo Nordisk A/S, Metacrine, Inc., Hepagene (Shanghai) Co., Ltd., TaiwanJ Pharmaceuticals Co., Ltd, Viking Therapeutics, Inc., LG Chem, Redx Pharma, and others are developing novel nonalcoholic steatohepatitis drugs that can be available in the nonalcoholic steatohepatitis market in the coming years.
• Some of the key therapies for nonalcoholic steatohepatitis treatment include RESMETIROM, Obeticholic acid (OCA), Cotadutide solution, IVA337 (Lanifibranor), MSDC-0602K, Semaglutide, Belapectin, Aramchol, Saroglitazar Magnesium, HU6, BIO89-100, LPCN 1144, HTD1801, EFX, EYP001 (Vonafexor), Denifanstat (formerly TVB-2640), leronlimab (PRO 140), TERN-501, PXL065, EDP-305, K-877 (Pemafibrate), Icosabutate, HPG1860, Efinopegdutide (MK-6024), Mitiperstat (AZD4831), Aldafermin (NGM282), HM15211 (efocipegtrutide), Semaglutide (SEMA)/Cilofexor (CILO)/Firsocostat (FIR), CS0159 (Linafexor), ION224, Rencofilstat, ervogastat (PF-06865571), ervogastat (PF-06865571) + clesacostat (PF-05221304), Tirzepatide, ALN-HSD, ALN-PNP, GSK4532990, BI 456906, FM101, BOS-580, MN-001 (tipelukast), HepaStem, VK2809, NN9500, ECC4703, CB4211, ALG-055009, Miricorilant, ALT-801, JNJ-0795, AZD2693, EDP-297, ION839, ARO-PNPLA3, ION455, PNPLA3 siRNA, Undisclosed, hydroxysteroid dehydrogenase 17β13 (HSD17β13), HPG7233, HPG5119, TJC0265, VK1430, LR19131, LR19018, RXC007, and others.
• Several nonalcoholic steatohepatitis therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major nonalcoholic steatohepatitis market share @ Nonalcoholic Steatohepatitis Market Report

Nonalcoholic Steatohepatitis Overview

Nonalcoholic steatohepatitis (NASH) is a form of progressive liver injury that can lead to progressive fibrosis, cirrhosis, and end-stage liver disease. It is a prevalent chronic liver disease characterized by hepatic inflammation and damage caused by fat accumulation in the liver. Like adults, children with certain unfavorable situations can develop NAFLD and NASH. It is still unknown why some infants with NAFLD have basic fatty liver while others have NASH.

NAFLD and NASH do not usually cause symptoms. If the patient is experiencing NASH symptoms, they may feel exhausted or have pain in the upper right side of their abdomen, where the liver is located. Cirrhosis is frequently the first sign of liver disease, typically after several years of having NAFLD. Suppose a person has NASH and significant liver scarring. In that case, the following signs and symptoms of cirrhosis may occur: If someone with NAFLD/NASH develops cirrhosis, they are also at risk of developing a common type of liver cancer called hepatocellular carcinoma. Intense itching, ascites, easy bruising, bleeding, jaundice, spider-like blood vessels beneath the skin's surface, behavior changes, hepatic encephalopathy. A liver biopsy is the only test that can confirm NASH diagnosis and determine how serious the illness is. A liver biopsy can detect fibrosis at an earlier stage than elastography.

Nonalcoholic Steatohepatitis Epidemiology Segmentation

The nonalcoholic steatohepatitis epidemiology section provides insights into the historical and current nonalcoholic steatohepatitis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The nonalcoholic steatohepatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total NASH Prevalent Cases 
• Total NASH Diagnosed Prevalent Cases
• NASH Gender-specific Diagnosed Prevalent Cases
• NASH Severity-specific Diagnosed Prevalent Cases
• NASH Treatable Cases

Download the report to understand which factors are driving nonalcoholic steatohepatitis epidemiology trends @ Nonalcoholic Steatohepatitis Epidemiological Insights

Nonalcoholic Steatohepatitis Treatment Market 

There are currently no FDA, EMA, or PMDA (Pharmaceuticals and Medical Devices Agency) approved drugs for the treatment of NASH; however, researchers are investigating therapies that may improve these problems. The current front-line NASH treatment consists of lifestyle changes like diet and exercise. Aside from lifestyle changes, other therapy options for NASH have included off-label use of vitamin E and anti-diabetes drugs (e.g., pioglitazone and liraglutide). The American Association for the Study of Liver Diseases (AASLD) NAFLD practice recommendation statement suggests using vitamin E off-label in non-cirrhotic, non-diabetic individuals with biopsy-proven NASH and pioglitazone in diabetic patients with biopsy-proven NASH.

Vitamin E, recognized for its antioxidant properties, is regarded as a first-line pharmaceutical treatment for NASH, particularly when diet and other lifestyle adjustments are insufficient. Antifibrotic drugs can stop the progression of liver fibrosis and NAFLD to fibrotic NASH. Although the effects of pioglitazone (anti-diabetes drugs) on NASH histology in type 2 diabetes have been thoroughly studied, some concerns remain, including body weight gain, fluid retention, cancer incidence, and bone fracture. Other targets for NAFLD and NASH treatment include G protein-coupled receptors (GPCRs), estrogen-related receptor alpha (ERR), bone morphogenetic proteins (BMPs), and KLFs. By lowering food absorption and modifying gut hormone production and metabolic dysfunction, bariatric surgery or weight loss surgery is regarded as the most effective technique to manage obesity and diabetes.

To know more about nonalcoholic steatohepatitis treatment, visit @ Nonalcoholic Steatohepatitis Treatment Drugs 

Key Nonalcoholic Steatohepatitis Therapies and Companies

• RESMETIROM: Madrigal Pharmaceuticals, Inc.
• Obeticholic acid (OCA): Intercept Pharmaceuticals
• Cotadutide solution: AstraZeneca
• IVA337 (Lanifibranor): Inventiva Pharma
• MSDC-0602K: Cirius Therapeutics, Inc
• Semaglutide: Novo Nordisk A/S
• Belapectin: Galectin Therapeutics Inc.
• Aramchol: Galmed Research and Development, Ltd.
• Saroglitazar Magnesium: Zydus Therapeutics Inc.
• HU6: Rivus Pharmaceuticals, Inc.
• BIO89-100: 89bio, Inc.
• LPCN 1144: Lipocine Inc.
• HTD1801: HighTide Biopharma Pty Ltd
• EFX: Akero Therapeutics, Inc
• EYP001 (Vonafexor): Enyo Pharma
• Denifanstat (formerly TVB-2640): Sagimet Biosciences Inc.
• leronlimab (PRO 140): CytoDyn, Inc.
• TERN-501: Terns, Inc.
• PXL065: Poxel SA
• EDP-305: Enanta Pharmaceuticals, Inc
• K-877 (Pemafibrate): Kowa Company, Ltd.
• Icosabutate: NorthSea Therapeutics B.V.
• HPG1860: Hepagene (Shanghai) Co., Ltd.
• Efinopegdutide (MK-6024): Mercks
• Mitiperstat (AZD4831): AstraZeneca
• Aldafermin (NGM282): NGM Biopharmaceuticals, Inc
• HM15211 (efocipegtrutide): Hanmi Pharmaceutical Company Limited
• Semaglutide (SEMA)/Cilofexor (CILO)/Firsocostat (FIR): Gilead Sciences/ Novo Nordisk A/S
• CS0159 (Linafexor): Cascade Pharmaceuticals, Inc
• ION224: Ionis Pharmaceuticals, Inc.
• Rencofilstat: Hepion Pharmaceuticals, Inc.
• ervogastat (PF-06865571): Pfizer
• ervogastat (PF-06865571) + clesacostat (PF-05221304): Pfizer
• Tirzepatide: Eli Lilly and Company
• ALN-HSD: Alnylam Pharmaceuticals
• ALN-PNP: Alnylam Pharmaceuticals
• GSK4532990: GlaxoSmithKline
• BI 456906: Boehringer Ingelheim
• FM101: Future Medicine
• BOS-580: Boston Pharmaceuticals
• MN-001 (tipelukast): MediciNova
• HepaStem: Cellaion/Promethera Therapeutics
• VK2809: Viking Therapeutics, Inc.
• NN9500: Novo Nordisk A/S
• ECC4703: Eccogene
• CB4211: CohBar, Inc.
• ALG-055009: Aligos Therapeutics
• Miricorilant: Corcept Therapeutics
• ALT-801: Altimmune, Inc.
• JNJ-0795: Janssen Pharmaceutical K.K.
• AZD2693: AstraZeneca
• EDP-297: Enanta Pharmaceuticals, Inc
• ION839: Ionis Pharmaceuticals, Inc.
• ARO-PNPLA3: Arrowhead Pharma
• ION455: Ionis Pharmaceuticals, Inc.
• PNPLA3 siRNA: Eli Lilly and Company
• Undisclosed:Novo Nordisk A/S
• hydroxysteroid dehydrogenase 17β13 (HSD17β13): Metacrine, Inc.
• HPG7233: Hepagene (Shanghai) Co., Ltd.
• HPG5119: Hepagene (Shanghai) Co., Ltd.
• TJC0265:TaiwanJ Pharmaceuticals Co., Ltd
• VK1430: Viking Therapeutics, Inc.
• LR19131: LG Chem
• LR19018: LG Chem
• RXC007: Redx Pharma

Learn more about the FDA-approved drugs for nonalcoholic steatohepatitis @ Drugs for NASH Treatment 

Nonalcoholic Steatohepatitis Market Dynamics

The nonalcoholic steatohepatitis market is expected to change in the coming years. The NASH market is quite void due to the lack of any approved medication; there is a tremendous need for proper NASH treatment. The potential for effective NASH treatment in the future is expected to increase with the addition of numerous drugs to the pipeline of new therapeutics, a variety of candidate drugs for the treatment of NASH are currently being tested in phase II or III clinical trials, and some have demonstrated positive results. Drugs such as FXR agonists, THR agonists, PPAR agonists, GLP-1 agonists, and others are currently being researched to target the NASH population. Any drug licensed with greater safety and efficacy is expected to bring about significant changes in the overall nonalcoholic steatohepatitis market. In addition to approved treatments, first-line therapies such as vitamin E and pioglitazone may still benefit appropriately selected patients with or without diabetes.

Furthermore, the NASH pipeline is highly robust; many possible therapies are being studied for nonalcoholic steatohepatitis treatment, and it is safe to assume that the therapeutic space will substantially impact the nonalcoholic steatohepatitis market throughout the forecast period.

However, certain factors may affect the growth of the nonalcoholic steatohepatitis market. The launch of generics will threaten new emerging therapies due to their cost-effectiveness. Moreover, the nonalcoholic steatohepatitis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the nonalcoholic steatohepatitis market growth.

Scope of the Nonalcoholic Steatohepatitis Market Report

• NASH Therapeutic Assessment: Nonalcoholic Steatohepatitis current marketed and emerging therapies
• Nonalcoholic Steatohepatitis Market Dynamics: Attribute Analysis of Emerging Nonalcoholic Steatohepatitis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Nonalcoholic Steatohepatitis Market Access and Reimbursement

Discover more about nonalcoholic steatohepatitis drugs in development @ Nonalcoholic Steatohepatitis Clinical Trials

Table of Contents

Related Reports

Nonalcoholic Steatohepatitis Epidemiology

Nonalcoholic Steatohepatitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted nonalcoholic steatohepatitis epidemiology in the 7MM.

Nonalcoholic Steatohepatitis Pipeline

Nonalcoholic Steatohepatitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, among others.

Non-Alcoholic Fatty Liver Disease Market

Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.

Non-Alcoholic Fatty Liver Disease Pipeline

Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced non-alcoholic fatty liver disease companies, including AstraZeneca, Novartis, Pfizer, Roche, among others.

Non-Alcoholic Fatty Liver Disease Epidemiology

Non-Alcoholic Fatty Liver Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted non-alcoholic fatty liver disease epidemiology in the 7MM.

Other Trending Reports

Alcohol Use Disorder Market | Liver Cancer Market | Alcoholic Hepatitis - Market | Acute Liver Failure - Market | Liver Angiosarcoma - Market | Liver Cirrhosis - Market | Chronic Liver Disease - Market | Advanced Liver Cancer - Market | Acute On Chronic Liver Failure (ACLF) Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg